

Volume 6, No. 1 (Supplement)

June 2011

ISSN 1823-2140

The National University
with an INTERNATIONAL REACH



UNIVERSITI
KEBANGSAAN
MALAYSIA
National University of Malaysia

MEDICINE & Health

The Official Journal of The Faculty of Medicine UKM

7th Malaysia Indonesia Brunei Medical Sciences Conference "TOWARDS A HOLISTIC AND INTEGRATIVE APPROACH IN HEALTHCARE"



22nd - 24th July 2011

Equatorial Hotel, Bangi, Selangor,
MALAYSIA

officiated by

Y.B Datuk Rosnah Haji Abdul Rashid Shirlin
Deputy Minister of Health Malaysia

Organised by



COMPARISON OF CLINICAL EFFICACY BETWEEN GYNOFORT AND CANESTAN IN THE TREATMENT OF VULVOVAGINAL CANDIDIASIS

Yulianty A¹, Amelia AZ¹, Nur Azurah AG¹, Tzar Mohd NK², Zainul Rashid MR¹

Department of ¹Obstetrics and Gynaecology and ²Microbiology, University Kebangsaan Malaysia Medical Centre Malaysia, Kuala Lumpur, Malaysia

Background:

The objective of the study is to compare the efficacy of single dose Gynofort versus single dose Canestan in the treatment of Vulvovaginal candidiasis in nonpregnant patients.

Material and Methods:

One hundred and twelve patients, with clinically confirmed Vulvovaginal candidiasis, were randomized into two treatment groups; Canestan group received treatment with a single dose of clotrimazole 500 mg vaginal pessary and the Gynofort group was treated with single dose butoconazole nitrate 2% Site Release vaginal cream. Symptom relief was assessed at six and 24 hours and on days 3,7,14, 21 and 28 after treatment and included recurrence of symptoms. Student's t-test was used with significance level set at $p < 0.05$.

Results:

The main presenting complaints were vaginal discharge (78.6%), vulvovaginal itchiness (58.1%) and dysuria (42.0%). Overall, more patients in the Gynofort group achieved complete relief of each main symptom at each time period. Significantly, more patients in the Gynofort group had complete relief of vaginal discharge compared to the Canestan group at days 7, 14, 21 and 28 ($p < 0.05$). More patients in the Gynofort group were relieved of vulvovaginal itchiness compared to the Canestan group at days 14, 21 and 28 ($p < 0.05$). Also more patients in the Gynofort group were relieved of dysuria at 24 hours ($p = 0.007$) and day 3 ($p = 0.02$) comparatively. Seventeen patients (30.3%) in the Canestan group had symptom recurrence compared to only 5 (8.9%) in the Gynofort group ($p = 0.004$).

Conclusion:

Gynofort has greater efficacy compared to Canestan in the treatment of Vulvovaginal candidiasis.

Keywords :

Vulvovaginal candidiasis, vaginal discharge, vulvovaginal itchiness, dysuria.